A pilot trial for prevention of HCV transmission from donor to organ transplant recipient with short course glecapravir/pibrentasvir

Abstract We demonstrate that a 7-day course of glecaprevir/pibrentasvir started in the pre-operative period prevented transmission of hepatitis C virus (HCV) from viremic organ donors to 10 HCV-negative transplant recipients (2 heart, 1 lung, 6 kidney, and one heart/kidney) with 100% sustained virological response at 12 weeks.